article thumbnail

Oxford BioTherapeutics and Roche link on antibody cancer treatments

Pharmaceutical Technology

OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Antibody 288
article thumbnail

J&J antibody drug combination shows promise in multiple myeloma

Bio Pharma Dive

A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.

Antibody 357
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

Bio Pharma Dive

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 347
article thumbnail

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact.

Antibody 337
article thumbnail

AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody

Pharmaceutical Technology

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

Antibody 288
article thumbnail

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround.

Antibody 336
article thumbnail

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 307